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Molecular docking studies on InhA, MabA
and PanK enzymes from Mycobacterium
tuberculosis of ellagic acid derivatives from
Ludwigia adscendens and Trewia nudiflora
Jamil A. Shilpi1,2, Mohammad Tuhin Ali3, Sanjib Saha2, Shihab Hasan4,5, Alexander I. Gray1 and Véronique Seidel1*
Abstract
Purpose: There is an urgent need to discover and develop new drugs to combat Mycobacterium tuberculosis, the
causative agent of tuberculosis (TB) in humans. In recent years, there has been a renewed interest in the discovery
of new anti-TB agents from natural sources. In the present investigation, molecular docking studies were carried
out on two ellagic acid derivatives, namely pteleoellagic acid (1) isolated from Ludwigia adscendens, and
3,3′-di-O-methyl ellagic acid 4-O-α-rhamnopyranoside (2) isolated from Trewia nudiflora, to investigate their binding
to two enzymes involved in M. tuberculosis cell wall biogenesis, namely 2-trans-enoyl-ACP reductase (InhA) and
β-ketoacyl-ACP reductase (MabA), and to pantothenate kinase (PanK type I) involved in the biosynthesis of
coenzyme A, essential for the growth of M. tuberculosis.
Methods: Molecular docking experiments were performed using AutoDock Vina.
The crystal structures of InhA, MabA and PanK were retrieved from the RCSB Protein Data Bank (PDB).
Isonicotinic-acyl-NADH for InhA and MabA, and triazole inhibitory compound for PanK, were used as references.
Results: Pteleoellagic acid showed a high docking score, estimated binding free energy of −9.4 kcal/mol, for the
MabA enzyme comparable to the reference compound isonicotinic-acyl-NADH.
Conclusions: Knowledge on the molecular interactions of ellagic acid derivatives with essential M. tuberculosis
targets could prove a useful tool for the design and development of future anti-TB drugs.
Keywords: Mycobacterium tuberculosis, Ellagic acid derivatives, 2-trans-enoyl-ACP reductase (InhA), β-ketoacyl-ACP
reductase (MabA), Pantothenate kinase (PanK), Ludwigia adscendens, Trewia nudiflora
Background
Mycobacterium tuberculosis, the causative agent of tu-
berculosis (TB) in humans, is the leading bacterial
killer worldwide. It led to 1.5 million deaths in 2013.
TB rates are particularly high in developing countries
where, with HIV/AIDS and malaria, it creates a huge
burden on healthcare systems. The current recom-
mended treatment for TB involves a prolonged course
of a combination of antibiotics with toxic side-effects
and is associated with poor patient compliance. This
has led to the emergence of multi-drug resistant
(MDR) and extensively-drug resistant (XDR) strains of
M. tuberculosis (WHO 2014). The treatment of MDR-
TB requires expensive second-line drugs whilst XDR-
TB is often incurable. The number of anti-TB drugs
currently in the pipeline is insufficient to address this
major health challenge. Therefore, there is an urgent
need to discover and develop new and efficient drugs
against TB (Zumla et al. 2013). In addition to that,
new antimycobacterial agents are needed to improve
the treatment of chronic infections caused by non-
tuberculous mycobacteria which have become difficult
to treat (Johnson and Odell 2014).
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Several key enzymes involved in M. tuberculosis cell
wall biogenesis and physiological functions have become
attractive targets for the design of novel anti-TB agents
(Jackson et al. 2013). Two of the target proteins of inter-
est in this study, namely 2-trans-enoyl-ACP reductase
(InhA) and β-ketoacyl-ACP reductase (MabA), belong to
the type-II fatty acid elongation system (FAS-II). The lat-
ter is a complex group of enzymes responsible for the
production of very long chain fatty acid derivatives that
are key precursors to mycolic acids, the main constitu-
ents of M. tuberculosis cell wall (Marrakchi et al. 2000,
2002; Takayama et al. 2005). Both enzymes are function-
ally and structurally-related. They display the same spe-
cificity for long chain substrates and are similarly
inhibited by the front-line anti-TB drug isoniazid
(Quemard et al. 1995; Marrakchi et al. 2000, 2002;
Ducasse-Cabanot et al. 2004). Another target for the de-
velopment of novel anti-TB drugs is the enzyme panto-
thenate kinase (PanK, type I) involved in the
biosynthesis of the cofactor Coenzyme A (CoA) from
pantothenic acid, which is essential for the growth of M.
tuberculosis (Bjorkelid et al. 2013).
Natural sources represent a vast reservoir of
chemically-diverse molecules which can provide new
templates for drug design. There has been a renewed
interest in recent years in the discovery of antimycobac-
terial/anti-TB agents from natural sources (Guzman
et al. 2012; Dashti et al. 2014; Santhosh and Suriyanar-
ayanan 2014). Among these natural products, ellagic
acid derivatives are known to interfere with mycolic acid
biosynthesis (Kondo et al. 1979). Ludwigia adscendens
and Trewia nudiflora were selected as part of a project
on the discovery of antimicrobial products from Bangla-
deshi medicinal plants. We previously reported on the
phytochemical investigation of L. adscendens, leading to
the isolation of pteleoellagic acid (1) (Shilpi et al. 2010).
In this work, we report on the isolation of compound 2
from T. nudiflora and on molecular docking studies of 1
and 2 on InhA, MabA and PanK enzymes from M.
tuberculosis.
Methods
Isolation and characterisation of compound 2
The plant Trewia nudiflora L. was collected in Rajshahi,
Bangladesh, in May 2006 and a voucher specimen
(DACB 34427) was deposited at the Bangladesh National
Herbarium. The air-dried powdered stem bark (1.1 kg)
was subjected to accelerated solvent extraction using an
ASE 100® system (Dionex, UK) successively with n-hex-
ane, ethyl acetate and methanol. Operating conditions
comprised of four static cycles (one cycle = 8 min); oven
temperature 100 °C, flush volume 60 %, purge time
150 s, pressure 1400–1500 psi. The methanol extract
was successively partitioned with n-hexane, ethyl acetate
and butanol. The butanol phase was further fractionated
by vacuum liquid chromatography using silica gel 60H
(VWR International, UK). The fraction eluted with 35 %
methanol in ethyle acetate was chromatographed on a
C-18 silica column (10 g, Phenomenex, UK) using a
Flash Master Personal® system (Biotage, UK). Elution
with 100 % water, followed by gradual increases of acet-
one, yielded compound (2) (46 mg) as a light brown
amorphous solid. Characterisation work was performed
by a combination of mass spectrometry and 1H and 13C
nuclear magnetic resonance spectroscopy experiments,
acquired on a ThermoFinnigan LCQ- Orbitrap and a
JEOL- 400 Lambda Delta instrument, respectively.
R1 R2 R3 R4
1 CH2 CH3 H
2 CH3 -L-Rhamnosyl CH3 H
Fig. 1 Chemical structures of ellagic acid derivatives
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Molecular docking studies
Ligand and protein preparation
ChemBio3D Ultra 12.0 (www.cambridgesoft.com) was
used to draw the structures of compounds 1 and 2
(Fig. 1), optimise ligand geometry and run MM2 en-
ergy minimisation of the 3D structures (Allinger
1977). The structures of the experimental inhibitors,
isonicotinic-acyl-NADH for InhA and MabA, and tri-
azole inhibitory compound for PanK, were retrieved
from the respective protein crystal structures (PDB
ID: 1ZID and PDB ID: 4BFT, respectively). All file
conversions required for the docking study were per-
formed using the open source chemical toolbox Open
Babel version 2.3.2 (www.openbabel.org) (O’Boyle
et al. 2011). All rotatable bonds present on the li-
gands were treated as non-rotatable to perform the
rigid docking. The Gasteiger charge calculation
method was used and partial charges were added to
the ligand atoms prior to docking (Gasteiger and
Marsili 1980). The crystal structures of InhA (PDB
ID: 1BVR), MabA (PDB ID: 1UZN) and PanK (PDB
ID: 3AF3) were retrieved from the RCSB Protein Data
Bank (PDB) (www.rcsb.org/pdb/home/home.do). All
water molecules and hetero atoms were removed
from the crystal structures by using PyMOL molecu-
lar graphic system, version 1.5.0.3 (www.pymol.org).
Fig. 2 Molecular interactions between compound 1 and InhA.
a Docked pose of 1in the InhA binding site. The residues which
interact with 1 are marked in a hot pink colour. b Interactions
between 1 and InhA with the H-bond distances generated by
PyMOL. Dashed lines represent the H-bonds
Fig. 3 Molecular interactions between compound 2 and InhA.
a Docked pose of 2 in the InhA binding site. The residues which
interact with 2 are marked in a hot pink colour. b Interactions
between 2 and InhA with the H-bond distances generated by
PyMOL. Dashed lines represent the H-bonds
Table 1 Binding site residues and grid box parameters selected for the target enzymes
Protein name Binding site residues Centre grid box (points) Size (points) Spacing (Å)
InhA Met103, Phe149, Met155, Tyr158, Met161, Ala198, Met199, Ala201, Ile202,
Leu207, Ile215, Leu218, and Thr196.
12.832 × 16.388 × 6.306 20 × 20 × 20 1.0
MabA Gly22, Asn24, Ile27, Arg47, Asp61, Val62, Gly90, Asn88, Ser140, Ile138,
Gly139, Tyr153, Ile186, and Lys157.
3.561 × 17.242 × 11.951 22 × 22 × 22 1.0
PanK Gly97, Ser98, Val99, Ala100, Val101, Gly102, Lys103, Ser104, His179,
Tyr235, Arg238, Met242, Asn277
−40.278 × 34.674 × −5.52 20 × 20 × 20 1.0
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Identification of binding site residues
The binding site residues for InhA and MabA were
identified from previous studies (Rozwarski et al.
1999; Marrakchi et al. 2000; Rosado et al. 2012). The
active site residues of PanK were retrieved from the
analysis of the crystal structures of PanK in complex
with pantothenate (PDB ID: 3AF3) and the triazole
inhibitory compound (PDB ID: 4BFT) and its se-
quence annotation available in the Uniport database
(Accession number: P9WPA7).
Grid box preparation and docking
Docking experiments were performed with compound 1,
2 and the experimental control inhibitors against InhA,
MabA and PanK proteins. Grid box parameters (Table 1)
were set by using AutoDock Tools (ADT), a free graphic
user interface of MGL software packages (version
1.5.6rc3) (Morris et al. 2009). The molecular docking
program AutoDock Vina (version 1.1.2) (Trott and
Olson 2010) was employed to perform the docking ex-
periment. The Lamarckian Genetic Algorithm was used
during the docking process to explore the best conform-
ational space for the ligand with a population size of 150
individuals. The maximum numbers of generation and
evaluation were set at 27,000 and 2,500,000, respectively.
Other parameters were set as default (Table 1).
Results and discussion
The structure of compound 2 was established following
comparison of its physicochemical and spectroscopic
data with those previously reported (Kang et al. 2008)
(Fig. 1). Compounds 1 and 2 were selected for molecular
docking simulations because, unlike other ellagic acid
derivatives (3,4,3′-tri-O-methyl ellagic acid, 3,3′-di-O-
methyl ellagic acid and 3-O-methyl ellagic acid 4′-O-α
rhamnopyranoside), they had showed some activity in
vitro against Mycobacterium aurum (Shilpi 2009). The
latter is often used as a surrogate to M. tuberculosis in
screening assays because it shares a high level of similar-
ity with M. tuberculosis in its mycolic acid biosynthetic
pathways and in the standard drugs used to inhibit this
biosynthesis (Gupta et al. 2009). This prompted us to
further investigate the potential of 1 and 2 to interact
with selected enzymes that were essential to M.
Fig. 4 Molecular interactions between compound 1 and MabA.
a Docked pose of 1 in the MabA binding site. The residues which
interact with 1 are marked in a hot pink colour. b Interactions
between 1 and MabA with the H-bond distances generated by
PyMOL. Dashed lines represent the H-bonds
Fig. 5 Molecular interactions between compound 2 and MabA.
a Docked pose of 2 in the MabA binding site. The residues which
interact with 2 are marked in a hot pink colour. b Interactions
between 2 and MabA with the H-bond distances generated by
PyMOL. Dashed lines represent the H-bonds
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tuberculosis. The docked poses for each of the com-
pounds were evaluated and the pose with the lowest
binding free energy and the least root mean square devi-
ation was thereby chosen (Additional file 1: Figure S1).
The hydrogen bond interactions between the active
compounds and selected amino acid residues for each of
the target proteins are illustrated in Figs. 2, 3, 4, 5, 6 and
7. The molecular docking scores were calculated as the
predicted binding free energies in kcal/mol (Table 2).
The lowest binding free energy (i.e. best docking score)
indicated the highest ligand/protein affinity. The in silico
study was done in comparison with control compounds
(i.e. known inhibitors of the target enzymes). The con-
trols were isonicotinic-acyl-NADH for both InhA and
MabA and a recently identified triazole-derived com-
pound for PanK (Bjorkelid et al. 2013).
The predicted binding free energies observed for com-
pound 1 and 2 with InhA were −8.4 and −7.8 kcal/mol,
respectively. The binding free energy observed for
isonicotinic-acyl-NADH against InhA was −11.7 kcal/
mol. Compound 1 was found to establish hydrogen
bonds with Ile 95, Gly96, Lys165 and Thr196 (Fig. 2).
Isonicotinic-acyl-NADH interacted with Gly14, Ser20,
Ile21, Lys165 and Thr196 residues of InhA. The hy-
droxyl group of the Thr196 residue has been described
as a critical component of the substrate binding loop of
InhA as, in association with NAD, it helps to fix the sub-
strate on to its active site (Rozwarski et al. 1999). Com-
pound 2 interacted with Ser94 and Tyr158 residues of
InhA (Fig. 3). The X-ray crystallographic data published
for PDB ID: 1BVR shows that the hydroxyl group of the
Tyr158 residue is involved via hydrogen bonding in the
interaction between InhA and its natural substrate
(Rozwarski et al. 1999). In addition, the Ser94 residue
plays a crucial role in the interaction between InhA and
the isonicotinic-acyl-NADH complex. A mutation in the
Ser94 residue to Ala94 causes Mycobacterium to become
resistant to isoniazid (Rozwarski et al. 1998, 1999).
The binding free energies obtained for compounds 1
and 2 with MabA were −9.4 and −10.8 kcal/mol, re-
spectively. The binding free energy of compound 1 with
MabA was comparable with the control inhibitor
isonicotinic-acyl-NADH (−9.5 kcal/mol). Compound 1
established hydrogen bonds with the amino acid residues
Gly90, Gly139, Gly184, Lys157 and Thr188, while com-
pound 2 interacted with Arg25, Asn88, Ser92, Ser140
Fig. 6 Molecular interactions between compound 1 and PanK.
a Docked pose of 1 in the PanK binding site. The residues which
interact with 1 are marked in a hot pink colour. b Interactions
between 1 and PanK with the H-bond distances generated by
PyMOL. Dashed lines represent the H-bonds
Fig. 7 Molecular interactions between compound 2 and PanK.
a Docked pose of 2 in the PanK binding site. The residues which
interact with 2 are marked in a hot pink colour. b Interactions
between 2 and PanK with the H-bond distances generated by
PyMOL. Dashed lines represent the H-bonds
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and Tyr153 (Figs. 4 and 5). Isonicotinic-acyl-NADH
interacted with Gly22, Asn24, Arg25, Ile27, Asp61,
Asn88, Tyr153, Lys157, Thr188 and Thr191 residues of
MabA. Among these amino acids, the Ser140, Tyr153
and Lys157 residues are those associated with the cata-
lytic triad of MabA. The side chain of Tyr153 has a cen-
tral role in the acid–base catalysis performed by this
enzyme (Kavanagh et al. 2008). Any mutation in the
Ser140 residue causes a loss of enzyme activity (Rosado
et al. 2012). The amino acid Gly90 has been shown to be
involved in the complexation of MabA with its natural
NADPH cofactor while any mutation of Gly139 into
Ala139 causes complete protein inactivation by freezing
the catalytic triad into a closed form (Poncet-Montange
et al. 2007; Rosado et al. 2012).
The predicted binding energies for compounds 1 and
2 with PanK (type I) were −9.7 and −11.3 kcal/mol, re-
spectively. The triazole-derived control inhibitor showed
a binding energy of −10.6 kcal/mol towards PanK. Com-
pound 1 established hydrogen bonds with the amino
acid residues Ala100, Val101, Gly102, Lys103, Thr105
and Arg108 whereas compound 2 interacted with Lys103,
Ser104, Tyr123, Tyr182 and Arg238 (Figs. 6 and 7). The
triazole-derived control inhibitor displayed an interaction
only with the Tyr135 residue of PanK. The Ala100 to
Ser104 residues are known to be part of the PanK P-loop
which is responsible for the holding of ATP during
catalysis (Cheek et al. 2002; Bjorkelid et al. 2013). The
Arg238 acts as a connecting residue between the phos-
phorylated pantothenate and ATP, thereby aiding catalysis
(Chetnani et al. 2010).
Conclusions
Knowledge on the molecular interactions of natural
products with essential M. tuberculosis targets is a po-
tentially useful tool for the design and development of
new anti-TB drugs. This in silico study revealed that two
plant-derived compounds had the potential to interact
with selected enzymes that were essential to M. tubercu-
losis. One of them, identified as pteleoellagic acid (1)
had a docking score to MabA comparable to the control
inhibitory substrate for this enzyme. Further work is re-
quired to gain a better insight into structure-active site
relationships using a wider variety of structurally-related
derivatives as well as to correlate the results of the dock-
ing study with in vitro enzymatic experiments in the
search for new anti-TB drugs.
Additional file
Additional file 1: Figure S1. Docked complexes of compound 1 and
compound 2 at the protein binding sites. Docking of 1 (a) and 2 (b) with
InhA. Docking of 1 (c) and 2 (d) with MabA. Docking of 1 (e) and 2 (f)
with PanK. Surfaces represent the protein while sticks represent the active
compounds. Different surface colours were chosen to represent different
proteins. (JPG 306 kb)
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1 InhA −8.4 Ile95, Gly96, Lys165, Thr196.
MabA −9.4 Gly90, Gly139, Lys157, Gly184, Thr188.
PanK −9.7 Ala100, Val101, Gly102, Lys103, Thr105, Arg108.
2 InhA −7.8 Ser94, Tyr158.
MabA −10.8 Arg25, Ser92, Asn88, Ser140, Tyr153.
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Isonicotinic-acyl-NADH (control) InhA −11.7 Gly14, Ser20, Ile21, Lys165, Thr196.
MabA −9.5 Gly22, Asn24, Arg25, Ile27, Asp61, Asn88, Tyr153,
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